BioArctic publishes the Annual Report and Sustainability Report for 2025
BioArctic publishes the Annual Report and Sustainability Report for 2025
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP [Yahoo! Finance]
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference [Yahoo! Finance]